In vivo CAR engineering for immunotherapy

2025/05/16 by Yan-Ruide Li, Yichen Zhu, Tyler Halladay +1 · 1 voice · 3 citations
Biochemistry, Genetics and Molecular Biology · Engineering · Medicine · #CAR-T cell therapy research #Nanowire Synthesis and Applications #Viral Infectious Diseases and Gene Expression in Insects

paper · doi:10.1038/s41577-025-01174-1

crossref issued 2025/05/16 · crossref published 2025/05/16 · crossref published-online 2025/05/16 · openalex publication_date 2025/05/16 · crossref created 2025/05/16 · crossref deposited 2025/09/26 · crossref published-print 2025/10/01 · openalex created_date 2025/10/10 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/30

Citations

• Modulation of immune responses in lentiviral vector-mediated gene transfer
• Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology
• Macrophage-Based Approaches for Cancer Immunotherapy
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
• Viral vector platforms within the gene therapy landscape
• Targeting tumor-associated macrophages to synergize tumor immunotherapy
• Lipid nanoparticles for mRNA delivery
• Drug delivery systems for RNA therapeutics
• Macrophages as tools and targets in cancer therapy
• Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
• Managing allorejection in off-the-shelf CAR-engineered cell therapies
• Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies

Cited by

• CAR-neutrophils produced in vivo to treat glioma
• Autologous, allogeneic, in vivo CAR for autoimmune diseases
• Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

Discussions

• 👉 You are the bioreactor: A review on in vivo engineering to produce CAR T cells doi.org/10.1038/s415... [bsky, 1 points, 0 comments]